Fundz
New|Fundz now works inside Claude2 min

AI made execution free. Knowing first is the whole game now.

The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.

Trusted by

OracleSnowflakeCloudflareLinkedInGoogleSalesforce
4.8/5 on G2· Since 2015

ADARx Pharmaceuticals has priced its upsized IPO at $446.3 million, offering 26,250,000 shares at $17.00 each. The offering is set to close on September 28, 2026.

PUBLIC · ADRXSep 24, 2026

Amount Raised

$446 Million

Round Type

IPO

San DiegoBiotechnologyHealthcareHealth CareTherapeutics

Investors

Life Sci CapitalUbs Investment BankTd CowenMorgan StanleyJ.P. Morgan

Description

ADARx Pharmaceuticals, Inc. announced the pricing of its upsized initial public offering expected to raise approximately $446.3 million. The shares are set to begin trading on The Nasdaq Global Select Market on September 25, 2026. Lead managers for the offering include J.P

Company Information

Company

ADARx Pharmaceuticals, Inc.

Location

5871 OBERLIN DRIVE, SUITE 200

San Diego, California, United States

About

ADARx Pharmaceuticals is a newly launched next-wave genetic medicine company focusing on oligonucleotide therapeutics for inhibition, degradation and base editing of mRNA transcripts. With RNA as the target of our drug discovery, we are capable of working on a wide range of diseases and are currently focusing on genetic, cardiometabolic, and central nervous system (CNS) diseases. We are driven by our mission to turn cutting-edge science into life-saving therapeutics and our desire to provide hope for patients with intractable disease. We are well-financed with backup from a group of renowned VC funds, and our brand-new laboratory is located in San Diego, California.

Fundz sees it the moment ADARx Pharmaceuticals, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contacts Christopher C., Director hidden hidden hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for ADARx Pharmaceuticals, Inc.'s next move

See what Strategic adds

ADARx Pharmaceuticals, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 285,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.